Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ionis
Biotech
AstraZeneca drops GOLDILOX and the porcupine in R&D update
The drugmaker axed a cardiovascular disease prospect while stopping work on early-stage assets bought in from Ionis and Redx Pharma.
Nick Paul Taylor
Apr 25, 2024 3:24am
ACC: Efficacy ticks down a smidge for Ionis' metabolic drug
Apr 7, 2024 9:45am
MHRA CEO Raine to depart in Autumn —Chutes & Ladders
Mar 1, 2024 9:30am
Roche pays Ionis $60M to license Alzheimer's, Huntington's drugs
Sep 27, 2023 8:56am
Ionis' lipid-lowering drug hits phase 3 goal, teeing up filings
Sep 26, 2023 7:00am
Novartis bets $60M upfront on Ionis' next-gen cardiovascular med
Aug 3, 2023 11:15am